Calithera Biosciences names new board member
This article was originally published in Scrip
Calithera Biosciences, a clinical-stage pharmaceutical company developing small-molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, has named H Ward Wolff to its board of directors, where he will chair the company's audit committee. Mr Wolff is currently executive vice-president and chief financial officer of Sangamo BioSciences.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.